AbbVie (NYSE:ABBV) Issues Q3 2026 Earnings Guidance

Posted by Brenda Bartman on Oct 8th, 2026

AbbVie (NYSE:ABBV – Get Free Report) issued an update on its third quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 3.730-3.770 for the period, compared to the consensus estimate of 3.850. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Rothschild & Co Redburn boosted their price target on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Wells Fargo & Company boosted their target price on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Barclays increased their price target on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. HSBC boosted their price target on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Finally, Scotiabank boosted their target price on shares of AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $274.32.

Read Our Latest Stock Analysis on ABBV

AbbVie Stock Performance

NYSE ABBV opened at $271.37 on Thursday. AbbVie has a 52-week low of $190.75 and a 52-week high of $274.94. The company has a fifty day moving average of $258.27 and a 200-day moving average of $235.87. The company has a market capitalization of $479.44 billion, a P/E ratio of 76.66, a P/E/G ratio of 1.22 and a beta of 0.24.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the company posted $2.97 earnings per share. The company’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts forecast that AbbVie will post 13.93 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is 195.48%.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: The U.S. Food and Drug Administration granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations could accelerate development and regulatory review of the c-Met-directed antibody-drug conjugate, strengthening AbbVie’s oncology pipeline. AbbVie Temab-A Breakthrough Therapy Designations
Positive Sentiment: AbbVie and Genmab reported that Epkinly (epcoritamab) plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The Phase 3 result met its progression-free-survival goal and could support expanded use of Epkinly, potentially increasing its commercial opportunity and competitive position against Roche’s Polivy. AbbVie Epkinly Frontline DLBCL Results
Positive Sentiment: Scotiabank raised its AbbVie price target to $320 from $280 and maintained a “sector outperform” rating, citing the company’s growth prospects. The higher target adds to bullish analyst sentiment following the oncology updates. Scotiabank Raises AbbVie Price Target
Neutral Sentiment: AbbVie is scheduled to report third-quarter results later this month. Investors may look for evidence that newer products can offset long-term pressure from Humira and support the company’s full-year outlook. AbbVie Third-Quarter Earnings Preview
Negative Sentiment: AbbVie narrowed its third-quarter 2026 EPS guidance to $3.73–$3.77, below the $3.85 analyst consensus cited in reports. Separately, commentary highlighted a reported payout ratio above 190%, raising questions about the sustainability of the dividend if earnings or cash flow weaken. AbbVie Third-Quarter Guidance

AbbVie Company Profile

(Get Free Report)

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.